Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFIN-α2b in advanced metastatic melanoma: Eastern cooperative oncology group phase II trial E1696

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1443-1451

  Kirkwood, John M ^a,f   Lee, Sandra ^b   Moschos, Stergiosj ^a   Albertini, Mark R ^c   Michalak, John C ^d   Sander, Cindy ^a   Whiteside, Theresa ^a   Butterfield, Lisa H ^a   Weiner, Louis ^e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Siouxland Hematology Oncology Associates   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; EPITOPE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; IMMUNEX; PEPTIDE VACCINE; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON ALFA-2B; MALE; MELANOMA; MIDDLE AGED; VACCINATION;

EID: 63149171153     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1231     Document Type: Article

References (41)

1. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999:17: 2105-16.
2. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670-7.
3. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor (GM-CSF). J Clin Oncol 2000;18:1614-21.
4. Lawson D, Kirkwood JM. Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol 2000;18:1603-5.
5. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage NIB melanoma with high-dose interferon α-2b induces tumor regression via an immunomodulatory mechanism. J Clin Oncol 2006;24:3164- 71.
6. Panelli MC, Wang E, Phan G, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002;3:0035.1 -0035.17.
7. 7,Vuylsteke RJCLM, Molenkamp BG, Gietema HA, et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 2004;64: 8456-60.
8. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
9. Gogas H, loannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18.
10. Atkins M, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988:318: 1557-63.
11. Luiten RM, Kueter EWM, Mooi W et al. Immunoge-nicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol 2005;23: 8978-91.
12. Astsaturov I, PetrellaT, Bagriacik EU, et al. Amplication of virus-induced antimelanomaT-cell reactivity by high-dose interferon-α2b: implications for cancer vaccines. Clin Cancer Res 2003;9:4347-55.
13. Chianese-Bullock KA, Pressley J, Garbee C, et al. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte- macrophage colony stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multi-peptide vaccine for melanoma. J Immunol 2005:174: 3080-6.
14. Zarour H, Kirkwood JM. Melanoma vaccines: early progress and future promises. Semin Cutan Med Surg 2003;22:68-75.
15. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004;22:4474-85.
16. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
17. Wang F, Bade E, Kuniyoski C, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756-65.
18. Rosenberg SA.Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321 -7.
19. + T cell responses in humans. Proc Nat Acad Sci U S A 2004;101:10697-702.
20. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
21. Traversari C, van der Bruggen P, Leuscher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolyticT lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176:1453-7.
22. Wolfel X van Pel A, Brichard V, et al. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994;24:759-64.
23. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxicTcell lines. Science 1994;264:716-9.
24. van der Bruggen P,Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolyticT lymphocytes on a human melanoma. Science 1991; 254:1643-7.
25. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A1994;91: 6458-62.
26. Coulie PG, Brichard V, van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolyticT lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
27. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
28. + cytotoxicT lymphocytes. J Exp Med 1995;181:363-8.
29. Kirkwood JM, Bender C, Agarwala SS, et al. Mechanisms and management of toxicities associated with high-dose interferon α-2b therapy. J Clin Oncol 2002; 20:3703-18.
30. Yamshchikov G, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001;92:703-11.
31. Sondak VK, Liu P-Y,Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002;20: 2058-66.
32. Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002;20:4181 -90.
33. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003;13: 401-7.
34. Kirkwood JM, Ibrahim J, Sosman JA, et al. High- dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2- KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
35. Pass HA, Schwarz SL, Wunderlich JR, et al. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998;4:316-23.
36. Markovic SN, SumanVJ, Ingle JN, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol 2006;29: 352-60.
37. Lotem M, ZhaoY Riley J, et al. Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J Immunother 2006;29: 616-27.
38. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-α versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol 2005;23:9001 -7.
39. Keiholz U, Punt CJA, Gore M, et al. Dacarbazine, cisplatin, and interferon-α-2b with or without interleu-kin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23:6747-55.
40. Kirkwood JM, Richards T, Zarour HM. et al. Immunomodulatory effects of high-dose and low-dose interferon α 2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 2002;95:1101 -12.
41. Peterson AC, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induced clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003;21:2342-8.